@FierceMedDev:vIsrael's Lumenis is plowing ahead with a planned $100M IPO--device market wariness be damned. Story | Follow @FierceMedDev
@MarkHFierce: Philips scored a strategically smart remote patent monitoring deal with Boston's Partners Healthcare. Article | Follow @MarkHFierce
@MichaelGFierce: This week's Chutes&Ladders: Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone. Report | Follow @MichaelGFierce
@EmilyWFierce: No love for Aveo and Astellas: Companies 'breakup,' end pact to develop cancer drug. Article | Follow @EmilyWFierce
> Medtronic ($MDT) has quietly sold off a division that manufactured a medical device implant designed to treat snoring. Story
> B. Braun won a CE mark for a new stent designed to treat coronary artery stenosis. Item
> An ad featuring the surgery team from the University of Illinois Hospital promoting the use of Intuitive Surgical's ($ISRG) da Vinci surgical robot continues to generate controversy. Blog
> Money-losing Missouri medical device maker Stereotaxis ($STXS) made chairman William Mills III its new CEO. Story
> The U.S. FDA cleared a new catheter designed for the rectal delivery of medications and liquids, useful when patients are unable to swallow. Item
Biotech News
@FierceBiotech: Follow the money: Our John Carroll talks money, geography and biotech. Editor's Corner | Follow @FierceBiotech
@JohnCFierce: Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout. More | Follow @JohnCFierce
@DamianFierce: Astellas finally bails on $AVEO, giving up on the thrice-failed tivozanib. Story | Follow @DamianFierce
@EmilyMFierce: BioLineRx shows effectiveness of leukemia drug in preclinical study. Article via FierceBiotech Research | Follow @EmilyMFierce
> AstraZeneca may have a gout blockbuster on its hands with lesinurad. Story
> GlaxoSmithKline eyes rare disease to widen its respiratory lead. Piece
Pharma News
@FiercePharma: Here's why a crowdfunded HIV vaccine project is drawing criticism from some scientists. More | Follow @FiercePharma
@TracyStaton: Gilead won't make hep C sales projections, but doesn't mind if you do. Provided they're huge. Piece| Follow @TracyStaton
@EricPFierce: CEO Bresch's moves in India give Mylan low-cost production tied to a high-value rep. Report | Follow @EricPFierce
@CarlyHFierce: Shire steers Vyvanse toward binge eating as earnings come up aces. Article | Follow @CarlyHFierce
> Doxycycline sales power Hikma, but the party may be ending. News
> No FDA love for Xarelto in ACS patients. Story